Literature DB >> 2137363

Salmon calcitonin in the acute management of hypercalcemia.

L A Wisneski1.   

Abstract

Salmon calcitonin has been used for the management of acute hypercalcemia for the past several years. Unlike other hypocalcemic agents, it is effective within 2 hours after first dosing. This pharmacologic agent shows peak effect at 24-48 hours and has a duration of action of 4-7 days in most cases. Its effectiveness may diminish thereafter despite continuous administration (the so-called "escape phenomenon"). Salmon calcitonin has been shown to be effective in the management of acute hypercalcemia due to a variety of causes, and, because of its low toxicity profile, it may be administered to patients with congestive heart failure or azotemia. Salmon calcitonin is also an analgesic agent in patients with pain associated with bone metastases and may be used in conjunction with other hypocalcemic agents such as mithramycin, the bisphosphonates, or gallium nitrate to prolong the clinical response to more than 1 week. Salmon calcitonin is therefore effective and safe in the management of acute hypercalcemia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137363     DOI: 10.1007/bf02553290

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  24 in total

1.  Calcitonin treatment of hypercalcemia due to parathyroid carcinoma. Synergistic effect of prednisone on long-term treatment of hypercalcemia.

Authors:  W Y Au
Journal:  Arch Intern Med       Date:  1975-12

Review 2.  Medical management of the hypercalcemia of malignancy.

Authors:  L J Deftos; R Neer
Journal:  Annu Rev Med       Date:  1974       Impact factor: 13.739

3.  Effects of synthetic salmon calcitonin in patients with Paget's disease of bone.

Authors:  C R Hamilton
Journal:  Am J Med       Date:  1974-03       Impact factor: 4.965

4.  Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.

Authors:  S H Ralston; M D Gardner; F J Dryburgh; A S Jenkins; R A Cowan; I T Boyle
Journal:  Lancet       Date:  1985-10-26       Impact factor: 79.321

5.  Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy.

Authors:  M L Binstock; G R Mundy
Journal:  Ann Intern Med       Date:  1980-08       Impact factor: 25.391

6.  Pain killing with calcitonin in patients with malignant tumours.

Authors:  J Szántó; S József; J Radó; E Juhos; I Hindy; S Eckhardt
Journal:  Oncology       Date:  1986       Impact factor: 2.935

7.  Effectiveness of salmon calcitonin administered as suppositories in tumor-induced hypercalcemia.

Authors:  D Thiébaud; P Burckhardt; P Jaeger; M Azria
Journal:  Am J Med       Date:  1987-04       Impact factor: 4.965

8.  Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin.

Authors:  R P Warrell; R Israel; M Frisone; T Snyder; J J Gaynor; R S Bockman
Journal:  Ann Intern Med       Date:  1988-05       Impact factor: 25.391

9.  Salmon calcitonin in the treatment of bone metastases.

Authors:  S Serdengeçti; K Serdengeçti; U Derman; B Berkarda
Journal:  Int J Clin Pharmacol Res       Date:  1986

10.  A double-blind controlled trial of salmon calcitonin in pain due to malignancy.

Authors:  A C Hindley; E B Hill; M J Leyland; A E Wiles
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

View more
  12 in total

Review 1.  Salmon calcitonin: a review of current and future therapeutic indications.

Authors:  C H Chesnut; M Azria; S Silverman; M Engelhardt; M Olson; L Mindeholm
Journal:  Osteoporos Int       Date:  2007-12-11       Impact factor: 4.507

2.  Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy.

Authors:  S Fatemi; F R Singer; R K Rude
Journal:  Calcif Tissue Int       Date:  1992-02       Impact factor: 4.333

Review 3.  [Metabolic disorders as paraneoplastic syndromes].

Authors:  S Krug; P Michl
Journal:  Internist (Berl)       Date:  2018-02       Impact factor: 0.743

Review 4.  Symptom management in metastatic breast cancer.

Authors:  William Irvin; Hyman B Muss; Deborah K Mayer
Journal:  Oncologist       Date:  2011-08-31

5.  Twist on a classic: vitamin D and hypercalcaemia of malignancy.

Authors:  Juan C Osorio; Masha G Jones; Nina Schatz-Siemers; Stephanie J Tang
Journal:  BMJ Case Rep       Date:  2017-11-23

Review 6.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

7.  Long-term hypervitaminosis D-induced hypercalcaemia treated with glucocorticoids and bisphosphonates.

Authors:  Chase C Houghton; Susie Q Lew
Journal:  BMJ Case Rep       Date:  2020-04-29

Review 8.  Hypercalcemia of Malignancy: An Update on Pathogenesis and Management.

Authors:  Aibek E Mirrakhimov
Journal:  N Am J Med Sci       Date:  2015-11

9.  Genomics and mapping of teleostei (bony fish).

Authors:  Melody S Clark
Journal:  Comp Funct Genomics       Date:  2003

10.  Unmasking of primary hyperparathyroidism by Vitamin D therapy.

Authors:  S Bala; B Shah; P Rajput; P Rao
Journal:  Indian J Nephrol       Date:  2015 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.